<DOC>
	<DOCNO>NCT00622193</DOCNO>
	<brief_summary>The purpose study evaluate dos anamorelin safety efficacy patient non-small cell lung cancer .</brief_summary>
	<brief_title>Dose Range Study Anamorelin Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Cancer cachexia devastating , often late-stage complication underlie malignancy . Despite significant importance cancer-related cachexia , treatment lack product approve indication . Anamorelin HCl , virtue ghrelin agonist activity , may serve role treatment cancer cachexia . This placebo control dose range study evaluate safety efficacy anamorelin HCl patient non-small cell lung cancer , cancer associate high prevalence cachexia .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>stage IIIB IV NSCLC eligible treatment NSCLC paclitaxel carboplatin +/ bevacizumab mixed large small cell histology lung cancer significant obesity , BMI &gt; 30</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>NSCLC</keyword>
</DOC>